δ in Dementia Clinical Trials

Dementia Clinical Trial

— dND  

Official title:

Novel Methods for Clinical Trials in Dementia and Cognitive Decline

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05592678
• Other study ID #: HSC20220551H
• Secondary ID: R01AG080548
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• Start date: June 2024
• Est. completion date: November 2028

Study information

• Verified date: June 2024
• Source: The University of Texas Health Science Center at San Antonio
• Contact: Amy Saklad
• Phone: 210 567-8229
• Email: SAKLADA[@]uthscsa.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are:

• Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status?

• Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity?

• Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention?

• Is the effect of the intervention in fact medicated by changes in the targeted biomarker?

In this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called "adipokines"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes.

Participants with cognitive impairment and their caregivers will be interviewed by telephone and those with cognitive impairment will be treated for six-months with donepezil. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by δ, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.

Description:

Title: "Novel Methods for Clinical rials in Dementia and Cognitive Decline"

Study Description: This is a double-blind assignment open label clinical trial to test novel approaches to clinical trial methods. 1) The study team will pre-select cases most likely to benefit from adipokine modulation by a telephone assessment. 2) The study team will pre-select subjects with clinical and preclinical dementia most likely to respond to therapy. 3) The study team will test the drug donepezil's effect on dementia severity, in predicted responders and non-responders, as measured by a latent dementia phenotype "δ' and 4) test a latent Adipokines biomarker construct as a mediator of their association in the predicted responders.

Objectives:

Primary Objective: To test novel clinical trial methods relevant to dementia.

Secondary Objectives:

1. To test donepezil's effect on dementia severity as measured by δ.

2. To test Adipokines as a mediator of donepezil's effect on δ.

Endpoints: Primary Endpoint: Dementia severity as measured by the latent phenotype "δ" using the "dTEL" homolog.

Secondary Endpoint: Change in Adipokines as a mediator of donepezil's effect on dTEL.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: November 2028
• Est. primary completion date: November 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 100 Years

Eligibility

Inclusion Criteria:

• Ambulatory outpatient volunteers with competent informants. Competent informants are cognitively normal individual(s) who interacts with the person on a regular (at least 5 or more hours/week) basis and in the opinion of the PI can provide adequate collateral information on the participant's memory and cognitive status.

• Aged 65-100 years

• Clinical diagnosis of AD, or MCI. In Lieu of clinical diagnosis, the subject may proceed upon PI's review of cognitive testing done at pre-screening and baseline and their confirmation that the subject's scores are consistent with Mild Cognitive Impairment or Alzheimer's

• Capacity to give informed consent. If a patient is found to clinically decline during the course of the study and no longer able to provide consent, continued participation will be evaluated by the PI on a case-by-case basis.

• Geriatric Depression Scale (GDS) (15 item) score = 6

• No significant visual or hearing impairments

• A standardized dECog score between 0.0 and -1.0 relative to ADNI's cohort

• Assignment to "Group 1" by a LOI assessment of Adipokine adjusted v. unadjusted dECog scores.

Exclusion Criteria:

• A current self-reported diagnosis of "Major Depression" (treatment with "antidepressants" not exclusionary);

• A history of psychosis, including visual hallucinations;

• History or treatment for Parkinson's, or tremor, or Rapid Eye Movement (REM) behavior disorder;

• History or treatment for atrial fibrillation;

• History of bradycardia or syncopal events;

• Chronic diarrhea, h/o colonic resection or irritable bowel syndrome;

• Treatment for cancer in the last 5 years (excluding skin cancers);

• Major surgery in the last year;

• Treatment with anti-convulsants, mood stabilizers, neuroleptics, opiates, muscle relaxants, or systemic steroids.

• Current treatment with any AChEI or past treatment within the last year.

• Co-current treatment with any pharmacological intervention for dementia administered as either on or off label. Non-pharmacological interventions (e.g. Behavior Therapy) will be evaluated on a case by cases basis by the PI.

• In the opinion of the PI, treatment with AChEI is not appropriate due to a possible negative risk/benefit ratio based on past medical history or endorsement of symptoms during the screening interview.

• Co-participation in another study that the PI feels would pose a safety risk or adversely affect data integrity of this study.

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease (AD)
• Cognitive Decline
• Cognitive Dysfunction
• Dementia

Intervention

Drug:
• Donepezil
6 months of open label treatment at 10mg PO QD (maximum)

Locations

Country	Name	City	State
United States	Univeristy of Texas Health Science Center at San Antonio (UTHSCSA)	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Dementia "Reversion"	The frequency of dementia "reversion" defined as a final dTEL score > -0.40, i.e., the optimal d-score that discriminates subjects with AD from those with MCI in the Alzheimer's Disease Neuroimaging Initiative (ADNI).	Week 24
Primary	dTEL change	Change in a latent dementia-specific phenotype derived from cognitive assessment.	At baseline, and weeks 4, 12 and 24.
Secondary	ADIPOKINES change	Change in a latent construct derived from eight "Adipokine" proteins measured in blood.	Baseline and week 24.